Email
IZ Express #1,830: Influenza and clesrovimab recs, standing orders, Immunize.org commentary, and more
| From | Immunize.org <[email protected]> |
| Subject | IZ Express #1,830: Influenza and clesrovimab recs, standing orders, Immunize.org commentary, and more |
| Date | September 3, 2025 10:01 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed] [link removed] [link removed] [link removed]
Email not displaying correctly? View it in your browser. ([link removed])
[link removed]
Issue 1,830: September 3, 2025
Top Stories
* Immunize.org’s commitment to sharing clinical vaccination guidance based on the best available scientific evidence (#IZ1)
* “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025–26 Influenza Season” published in MMWR (#IZ2)
* Immunize.org’s standing order templates for the 2025–26 influenza season are now available (#IZ3)
* “Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025” published in MMWR (#IZ4)
* American College of Cardiology publishes clinical guidance for adults with cardiovascular disease, encouraging influenza, pneumococcal, COVID-19, RSV, zoster, and other vaccinations (#IZ5)
* FDA licenses updated COVID-19 vaccines for 2025–26 season with limited indications for people younger than age 65 (#IZ6)
* Immunize.org updates “Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy” to reference both preventive antibody options for infant RSV prevention (#IZ7)
* FDA suspends license for chikungunya vaccine live (Ixchiq, Valneva) based on safety concerns involving chikungunya-like illness (#IZ8)
* Immunize.org updates “Meningococcal B Vaccine Recommendations by Age and Risk Factor” to include both pentavalent MenABCWY vaccine options (#IZ9)
* Immunize.org updates resource “Before You Vaccinate Adults, Consider Their ‘H-A-L-O’!” (#IZ10)
* Confirmed measles cases in 2025 increase to 1,408 across 42 states; Alabama reports first case for 2025 (#IZ11)
* “Do Parents Have a Choice of How to Prevent RSV in Their Newborn?” Watch the 2-minute answer, part of the Ask the Experts Video Series on YouTube. (#IZ12)
* Journalists interview Immunize.org experts (#IZ13)
* Vaccines in the news (#IZ14)
Immunize.org Website and Clinical Resources
* Spotlight on the LetsGetRealAboutVaccines.org website: Help Patients (#IZ15)
* Recap: Immunize.org posts RSV preventive antibody standing order templates for clesrovimab (new) and nirsevimab (updated) (#IZ16)
* Summary: Updated Immunize.org clinical resources released in July and August (#IZ17)
Featured Resources
* Explore the www.Give2MenACWY.org website to increase coverage for the MenACWY booster and other adolescent vaccinations (#IZ18)
Upcoming Events
* Virtual: Register for Immunize.org Website Office Hours. Join a 30-minute discussion about the VIS web section on September 10 at 4:00 p.m. (ET) or September 11 at 12:00 p.m. (ET). Recorded sessions archived. (#IZ19)
* Virtual: Public Health Communications Collaborative offers webinar titled “Communicating with Heart in Public Health” on September 10 at 4:30 p.m. (ET) (#IZ20)
* Virtual: Maternal Immunization Task Force offers webinar titled “Preparing for Respiratory Virus Season: A Review of Maternal Immunization Guidance and Communication Strategies to Increase Vaccine Uptake and Confidence” on September 17 at 5:00 p.m. (ET) (#IZ21)
* Virtual: September 18–19 ACIP meeting announced; discussion and possible votes on COVID-19, hepatitis B, MMRV, and RSV vaccines planned (#IZ22)
Editorial Information (#Editorial)
------------------------------------------------------------
Top Stories
------------------------------------------------------------
Immunize.org’s commitment to sharing clinical vaccination guidance based on the best available scientific evidence
The recent changes to the membership of ACIP and resignation of respected scientific leaders at CDC have raised serious concerns across public health and healthcare communities. Information shared by the departing CDC leaders have raised doubts about the scientific validity of vaccine policies contemplated by the current administration. In addition, we observed the June ACIP vote against the use of thimerosal-containing influenza vaccines, a decision made without following the standard rigorous review of available data or the structured evidence-to-recommendations framework. In response, professional medical societies (e.g., American Academy of Pediatrics, American College of Obstetricians and Gynecologists) have begun to issue vaccination guidance that differs from new CDC guidance. Vaccination providers and educators who depend on Immunize.org resources should understand how we are approaching this unprecedented situation.
First, Immunize.org will continue to ensure vaccination providers know what CDC and ACIP recommend. Their recommendations directly affect VFC, Medicaid, and Medicare vaccine coverage, and could impact other insurance plan coverage. Federal recommendations may also define the permitted scope of practice for some vaccinators, including pharmacists, depending upon state regulations. We will provide context to help our readers understand when available scientific evidence does not support federal guidance.
Second, we will continue to educate vaccinators and share the best available evidence-based clinical information and guidance for vaccination. This may include adding links to the recommendations and published schedules of professional societies or other broadly accepted clinical guidance organizations. When we update resources with guidance from other credible scientific sources, we will be explicit about where that guidance came from and connect you to those sources.
Our goal is to support you to be able to make the best possible clinical practice decisions and provide the best available vaccination advice to your patients and families. To this end, our popular standing orders templates will include CDC recommendations and, when needed, refer to major professional society recommendations where there are important differences. As always, our standing orders templates should be adapted as needed to develop the standing orders you use in specific settings.
Immunize.org is in the process of determining the best ways to reflect these differences on our website clearly and concisely. We commit to keeping you, our readers and partners, informed as we proceed. We remain committed to supporting you and members of the public with trustworthy vaccination information and resources.
Back to top (#Top)
------------------------------------------------------------
“Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025–26 Influenza Season” published in MMWR
CDC published Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025–26 Influenza Season ([link removed]) on August 28 in MMWR. A portion of the summary appears below.
Information for the 2025–26 influenza season includes the updated vaccine composition, approval of FluMist (nasal spray live attenuated influenza vaccine) for self-administration or caregiver administration, expansion of the approved age threshold for Flublok (recombinant influenza vaccine) from ≥18 years to ≥9 years, and a recommendation that only single-dose seasonal influenza vaccines not containing thimerosal as a preservative be used. . . .
Routine annual influenza vaccination is recommended for all persons aged ≥6 months without a contraindication to vaccination to protect against influenza and its complications.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Links
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
* CDC: ACIP Recommendations: Influenza (Flu) Vaccine ([link removed]'s%20no%20need%20to%20wait,dose%201%20and%20dose%202) main page
* AAP:[link removed]'s%20no%20need%20to%20wait,dose%201%20and%20dose%202Which Flu Vaccine Should Children Get? ([link removed]) web page
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) main page
Back to top (#Top)
------------------------------------------------------------
Immunize.org’s standing order templates for the 2025–26 influenza season are now available
Immunize.org’s popular standing orders templates for the 2025–26 influenza season are now available. These templates help you simplify providing influenza vaccine to people in your practice age 6 months and older, whether you are using an injectable influenza vaccine or a live attenuated influenza vaccine.
* Standing Orders for Administering Influenza Vaccine to Adults ([link removed])
* Standing Orders for Administering Influenza Vaccine to Children and Teens ([link removed])
These templates are designed to be used with any formulation of influenza vaccine. They acknowledge the June 2025 ACIP vote to no longer recommend use of multi-dose vial formulations containing thimerosal as a preservative and note that CDC’s website ([link removed]) states (as of 8/30/2025) that there is no evidence of harm caused by the low doses of thimerosal in vaccines, other than minor reactions like redness and swelling at the injection site.
[link removed] [link removed]
Influenza Vaccine Products for the 2025–2026 Influenza Season ([link removed]) , Immunize.org’s one-page reference document, is also available. For each vaccine, the manufacturer, trade name, common abbreviation, dosage form, mercury content, age range, vaccine product (CVX) code, and product billing (CPT) code are listed.
[link removed]
Related Links
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) web page
* Immunize.org: Clinical Resources: Standing Orders Templates ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
“Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025” published in MMWR
CDC published Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025 ([link removed]) on August 28 in MMWR. A portion of the summary appears below.
To prevent respiratory syncytial virus (RSV)–associated lower respiratory tract infection (LRTI) in infants, since 2023, the Advisory Committee on Immunization Practices (ACIP) has recommended either 1) maternal RSV vaccination during pregnancy or 2) administration of nirsevimab, a long-acting RSV monoclonal antibody, to the infant. . . .
On June 26, 2025, ACIP recommended clesrovimab, a newly licensed long-acting RSV monoclonal antibody, as an alternative to nirsevimab for infants aged <8 months born during or entering their first RSV season who did not receive protection through maternal RSV vaccination. . . .
All infants should be protected against RSV LRTI through either maternal RSV vaccination or receipt of a long-acting RSV monoclonal antibody (clesrovimab or nirsevimab).
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Links
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
* Immunize.org: Standing Orders for Administering Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants ([link removed])
Back to top (#Top)
------------------------------------------------------------
American College of Cardiology publishes clinical guidance for adults with cardiovascular disease, encouraging influenza, pneumococcal, COVID-19, RSV, zoster, and other vaccinations
On August 26, the American College of Cardiology (ACC) published 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Adult Immunizations as Part of Cardiovascular Care: A Report of the American College of Cardiology Solution Set Oversight Committee ([link removed]) . A portion of the introduction appears below.
This CCG [Concise Clinical Guidance] provides current recommendations for vaccination in patients with cardiovascular disease along with more detailed justifications for those interested in the evidence influencing these recommendations. The intended audience is clinicians managing patients with cardiovascular disease (CVD). We include recommendations from existing ACC/American Heart Association (AHA) Guidelines and the Centers for Disease Control and Prevention (CDC) that are relevant, and evidence based. A Frequently Asked Questions section also provides information that can be used for patient discussions. The topic was selected by the ACC Science and Quality Committee. A summary of the recommendations is shown in Table 1.
[link removed]
The guidelines highlight helpful supplementary material, including patient handouts and communication approaches for cardiologists.
* Protect Your Heart with the Vaccines You Need ([link removed]) : an infographic to display in clinical settings, such as exam rooms or waiting rooms, to inform patients with heart disease about the vaccines they need to stay healthy
* Communication Approaches to Help Make a Strong Vaccine Recommendation ([link removed]) : a 17-page guide with practical tips to enhance conversations with patients about the importance of adult vaccines
[link removed] [link removed]
Related Links
* Immunize.org: Vaccinations for Adults with Heart Disease ([link removed])
* Immunize.org: Vaccinations for Adults with Heart Disease (Spanish) ([link removed])
Back to top (#Top)
------------------------------------------------------------
FDA licenses updated COVID-19 vaccines for 2025–26 season with limited indications for people younger than age 65
On August 27, FDA licensed updated COVID-19 vaccines for the 2025–26 season. The package insert indications were narrowed to include use in all people who are age 65 years and older and certain people younger than age 65 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. The indicated age ranges vary by vaccine, as described below.
Package inserts and approval letters appear at the links below.
* Spikevax (COVID-19 Vaccine, mRNA; Moderna) ([link removed]) : age 6 months through 64 years with an underlying condition and all adults age 65 years and older
* Comirnaty (COVID-19 Vaccine, mRNA; Pfizer/BioNTech) ([link removed]) : age 5 through 64 years with an underlying condition and all adults age 65 years and older
* Mnexspike (COVID-19 Vaccine, mRNA; Moderna) ([link removed]) : age 12 through 64 years with an underlying condition and all adults age 65 years and older
* Nuvaxovid (COVID-19 Vaccine, Adjuvanted; Novavax) ([link removed]) : age 12 through 64 years with an underlying condition and all adults age 65 years and older
At its September 18–19 meeting ([link removed]) , ACIP is scheduled to consider its recommendations for use of available COVID-19 vaccines.
In response to these limited indications, the Infectious Diseases Society of America (IDSA) ([link removed]) and the American Academy of Pediatrics (AAP) ([link removed]) each expressed serious concerns. Portions of their press releases appear below.
IDSA Statement (8/27/25): ([link removed])
COVID-19 vaccines remain our best tool to prevent severe disease, hospitalization and death due to COVID-19 — for healthy adults, children, pregnant patients and others at higher risk. The scientific evidence continues to strongly support broad vaccination far beyond the limited populations outlined in the Food and Drug Administration’s new label.
AAP Statement (8/27/25): ([link removed])
As we enter respiratory virus season, any barrier to COVID-19 vaccination creates a dangerous vulnerability for children and their families. Respiratory illnesses can be especially risky for infants and toddlers, whose airways and lungs are small and still developing.
Related Links
* Immunize.org: Vaccines A–Z: COVID-19 ([link removed]) main page
* FDA: Vaccines Licensed for Use in the United States ([link removed]) web page
* AAP: Recommended Child and Adolescent Immunization Schedules for Ages 18 Years or Younger, United States, 2025 ([link removed])
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates “Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy” to reference both preventative antibody options for infant RSV prevention
Immunize.org updated its Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy ([link removed]) , to note the options to use nirsevimab (Beyfortus ([link removed]) , Sanofi) or clesrovimab (Enflonsia, Merck) ([link removed]) for infant RSV protection if the mother was not effectively vaccinated during her pregnancy.
[link removed]
Related Links
* Immunize.org: Clinical Resources: Standing Orders Templates ([link removed]) main page
* Immunize.org: Vaccines A–Z: RSV (Respiratory Syncytial Virus) ([link removed]) main page
* Immunize.org: Standing Orders for Administering Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants ([link removed])
* Immunize.org: Standing Orders for Administering Nirsevimab RSV Preventive Antibody (Beyfortus, by Sanofi) to Infants and High-Risk Young Children ([link removed])
Back to top (#Top)
------------------------------------------------------------
FDA suspends license for chikungunya vaccine live (Ixchiq, Valneva) based on safety concerns involving chikungunya-like illness
On August 22, FDA suspended the license ([link removed]) for the live chikungunya vaccine Ixchiq (Valneva) ([link removed]) . This vaccine was initially approved by FDA in November 2023 ([link removed]) for the prevention of disease caused by chikungunya virus (CHIKV) in adults at increased risk of exposure to CHIKV. Concerns about side effects of this vaccine were first raised at the ACIP meeting in April 2025, when CDC presented details of six U.S. vaccine recipients age 65 years or older ([link removed]) , each with other health conditions, who developed cardiac or neurologic symptoms requiring hospitalization within days of vaccination. After additional monitoring and
reports of 20 similar serious illnesses in the United States and other countries, FDA suspended the license. One death from encephalitis attributed to the vaccine was reported from another country.
The viral-like particle chikungunya vaccine (Vimkunya, Bavarian Nordic), licensed in the United States in February 2025 for people age 12 years and older, continues to be recommended for use. It is not a live vaccine and is not associated with the safety concerns identified with the live-attenuated vaccine.
According to the European Centre for Disease Prevention and Control ([link removed]) , from January to July 2025 around 240,000 chikungunya cases and 90 related deaths have been reported in 16 countries or territories in the Americas, Africa, Asia, and Europe.
Related Links
* Valneva: Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. ([link removed]) (8/25/25)
* FDA: FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live) ([link removed]) web page
* CDC: Chikungunya Vaccine Information for Healthcare Providers ([link removed]) web page
* Immunize.org: Vaccines A–Z: Chikungunya ([link removed]) main page
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates “Meningococcal B Vaccine Recommendations by Age and Risk Factor” to include both pentavalent MenABCWY vaccine options
Immunize.org updated Meningococcal B Vaccine Recommendations by Age and Risk Factor ([link removed] ) to add the second pentavalent MenABCWY vaccine (Penmenvy, GSK ([link removed]) ([link removed]) ) in addition to Penbraya (Pfizer).
[link removed]
Related Link
* Immunize.org: Vaccines A–Z: Meningococcal B ([link removed]) web page
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates resource “Before You Vaccinate Adults, Consider Their ‘H-A-L-O’!”
Immunize.org recently updated its popular resource for healthcare professionals titled Before You Vaccinate Adults, Consider Their “H-A-L-O” ([link removed]) !
H-A-L-O refers to four factors:
* Health condition
* Age
* Lifestyle
* Occupation
Edits incorporate the age 50 threshold for adults with risk factors to receive RSV vaccine and referral to current recommendations for COVID-19 vaccine.
[link removed]
Related Links
* Immunize.org: Clinic Tools: Vaccine Recommendations ([link removed]) web page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
Confirmed measles cases in 2025 increase to 1,408 across 42 states; Alabama reports first case for 2025
As of August 27, CDC reported 1,408 confirmed measles cases ([link removed]) in 2025 in 42 states. Of reported confirmed cases, 28% were younger than age 5 years and 21% were hospitalized. Canada reports 4,718 confirmed and probable cases for 2025 through August 16.
CDC only requires reporting of laboratory-confirmed measles cases. Cases without laboratory testing for confirmation are not included in these numbers. Actual numbers of cases are, therefore, higher than confirmed case counts.
A map of 2025 measles cases ([link removed]) in the contiguous United States, as of August 25, from the Johns Hopkins International Vaccine Access Center ([link removed]) , appears below. The U.S. Measles Tracker ([link removed]) website includes state and county-level data.
[link removed]
Immunize.org offers measles-related resources for the public on several of our affiliated websites:
* VaccineInformation.org: Measles ([link removed]) web page
* LetsGetRealAboutVaccines.org: Measles ([link removed]) web page
* Immunize.org: Vaccines A–Z: Measles ([link removed]) main page
Another credible source is the American Academy of Pediatrics’ Fact Checked: The Measles Vaccine is Safe and Effective ([link removed]) web page.
Related Links
* CDC: Measles Cases and Outbreaks ([link removed]) main page
* CDC: Be Ready for Measles Toolkit ([link removed])
* Health Canada: Measles and Rubella Weekly Monitoring Report ([link removed])
* Johns Hopkins Bloomberg School of Public Health Center for Outbreak Response Innovation: Measles Outbreak Response ([link removed]) main page
* Immunize.org: Vaccines A–Z: Measles ([link removed]) main page
Back to top (#Top)
------------------------------------------------------------
“Do Parents Have a Choice of How to Prevent RSV in Their Newborn?” Watch the 2-minute answer, part of the Ask the Experts Video Series on YouTube.
This week, our featured episode from the Ask the Experts Video Series is titled Do Parents Have a Choice of How to Prevent RSV in Their Newborn? ([link removed] ) The video describes that mothers have options to choose Abrysvo, Pfizer’s brand of RSV vaccine during pregnancy or an RSV preventive antibody product for the infant after birth.
The 2-minute video is available on our YouTube channel ([link removed]) , along with our full collection of quick video answers to popular Ask the Experts ([link removed]) questions.
[link removed]
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
Back to top (#Top)
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a recent citation.
* CNN: After Narrowing COVID-19 Vaccine Approval, the FDA Says Healthy People Can Still Get It. But Access Might Be Complicated ([link removed]) (8/29/25)
* NPR: The Latest COVID Vaccines Come with New FDA Limits ([link removed]) (8/27/25)
Back to top (#Top)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* New York Times: We Ran the C.D.C.: Kennedy Is Endangering Every American’s Health ([link removed]) (commentary, 9/01/25)
* CBS: CVS and Walgreens Limit Access to COVID Vaccines as Required by Some State Guidelines ([link removed]) (8/29/25)
* Medpage Today: I Was Inside CDC During the Shooting. I Can Still Hear the Bullets. ([link removed]) (8/26/25)
* USA Today: Vaccine Skepticism Crisis Spills Over as Students Return to School ([link removed]) (8/25/25)
* PBS: Fact-Checking RFK Jr.’s Claim That Pediatricians Recommend Vaccines for Money ([link removed]) (8/24/25)
Back to top (#Top)
------------------------------------------------------------
Immunize.org Website and Clinical Resources
------------------------------------------------------------
Spotlight on the LetsGetRealAboutVaccines.org website: Help Patients
This week’s spotlight completes the review of our newest website, LetsGetRealAboutVaccines.org ([link removed]) , a trustworthy, parent-friendly platform that delivers factual vaccine guidance. It equips families and providers with tools to advocate for childhood immunization confidently.
This week’s focus is on the Help Patients ([link removed]) section. Found at the fourth menu tab, these pages share strategies for healthcare providers to communicate effectively with parents about vaccination.
[link removed]
The ARM Approach ([link removed]) for healthcare providers is an evidence-based, provider-reviewed, three-step approach (Act, Recommend, Motivate) to fruitful vaccine conversations with parents and patients. Content includes what, why, and how of making strong recommendations, and best practices to help patients make informed decisions.
Resources to use and share:
* Making effective recommendations [PDF ([link removed]) ]
* Sample outreach scripts and best practices [PDF] ([link removed])
* Videos
+ Dr. Marcy Solomon Baker ([link removed]) confirms most parents get their kids vaccinated
+ Dr. Todd Wolynn ([link removed]) explains that misinformation does not change the facts: vaccines are safe and effective
* Tips and timesavers [PDF ([link removed]) ]
Share these links with anyone seeking credible, unbiased information about childhood vaccines.
View the archived Website Office Hours: Let's Get Real About Vaccines ([link removed]) website webinar to learn simple tips and tricks for using the website efficiently.
Back to top (#Top)
------------------------------------------------------------
Recap: Immunize.org posts RSV preventive antibody standing order templates for clesrovimab (new) and nirsevimab (updated)
In response to new CDC recommendations for routine use of an additional RSV preventive antibody product in infants, Immunize.org published the clinical resource: Standing Order for Administering Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants ([link removed]) . Immunize.org also updated its existing Standing Order for Administering Nirsevimab RSV Preventive Antibody (Beyfortus, by Sanofi) to Infants and High-Risk Young Children ([link removed]) .
The new preventive antibody product, Enflonsia, is an option for protection of infants younger than age 8 months before or during their first RSV season. There is no preference between Beyfortus and Enflonsia for eligible infants. The Beyfortus standing orders template was updated to note that the other two options for protection of infants during their first RSV season are to administer Enflonsia to the infant or to administer the Abrysvo RSV vaccine (Pfizer) during pregnancy. Only Beyfortus is licensed and recommended for older children, age 8 through 19 months, who are at high risk for severe RSV disease and are entering their second RSV season.
Back to top (#Top)
------------------------------------------------------------
Summary: Updated Immunize.org clinical resources released in July and August
IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials for healthcare professionals and handouts for patients. All Immunize.org materials are free to distribute.
In case you missed them during recent weeks, the following new and updated materials were posted:
Immunize.org Materials for Clinicians
Standing Orders Templates for Administering:
* Respiratory Syncytial Virus Vaccine (RSV) to Adults Age 50 Years and Older ([link removed])
* Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy ([link removed])
* Nirsevimab RSV Preventive Antibody (Beyfortus, by Sanofi) to Infants and High-Risk Young Children ([link removed])
* Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants ([link removed])
* Zoster Vaccine (Shingrix) ([link removed])
Materials Supporting Immunization Services:
* Influenza Vaccine Products for the 2025–2026 Influenza Season ([link removed])
* Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed])
Immunize.org Webinars:
* Website Office Hours: Let's Get Real About Vaccines Website ([link removed])
* Website Office Hours: Official Guidance – State Resources ([link removed])
State Immunization Requirements, Exemptions, and Related Websites:
* COVID-19 Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* DTaP (Diphtheria-Tetanus-Pertussis) Vaccine Requirements for Childcare and Elementary School ([link removed]) as of May 2025
* Hepatitis A Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* Hepatitis B Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* Hepatitis B Vaccine Requirements for Colleges and Universities ([link removed]) as of May 2025
* Hib Vaccine Requirements for Childcare ([link removed]) as of May 2025
* HPV (Human Papillomavirus) Vaccine Requirements for Secondary School ([link removed]) as of May 2025
* Influenza Vaccine Requirements for Childcare and Pre-K ([link removed]) as of May 2025
* Meningococcal ACWY (MenACWY) Vaccine Requirements for Secondary School ([link removed]) as of May 2025
* Meningococcal ACWY (MenACWY) Vaccine Requirements for Colleges and Universities ([link removed]) as of May 2025
* MMR (Measles-Mumps-Rubella) Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* Pneumococcal Conjugate Vaccine (PCV) Requirements for Childcare ([link removed]) as of May 2025
* Polio Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* Rotavirus Vaccine Requirements for Childcare ([link removed]) as of May 2025
* Tdap (Tetanus-Diphtheria-Pertussis) Vaccine Requirements for Secondary School ([link removed]) as of May 2025
* Varicella Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* Exemptions Permitted for State Childcare and School (K–12) Immunization Requirements ([link removed]) as of May 2025
* State Immunization Websites ([link removed])
Back to top (#Top)
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Explore the www.Give2MenACWY.org website to increase coverage for the MenACWY booster and other adolescent vaccinations
Immunize.org's www.Give2MenACWY.org ([link removed]) website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines, so vaccine outreach is more important than ever.
Materials on this colorful website for healthcare professionals incorporate the 2020 ACIP meningococcal vaccine recommendations ([link removed]) and coverage statistics from CDC’s National Immunization Survey–Teen (NIS–Teen). One particularly popular resource on the site is the Algorithm for MenACWY Immunization in Adolescents 11 Through 18 Years of Age ([link removed]) .
[link removed]
The website is divided into five easy-to-access sections:
* Vaccinate Teens ([link removed]) : teen vaccination schedules and tips for improving vaccination rates
* Give 2 Doses ([link removed]) : tools to help improve second dose coverage of MenACWY vaccine
* 16-Year-Old Visit ([link removed]) : resources to help providers and patients remember the important vaccines recommended for 16-year-olds
* Tools for Providers ([link removed]) : tools to explain meningococcal ACWY vaccine recommendations and improve coverage for all adolescent vaccines
* Resources ([link removed]) : links to print materials ([link removed]) , organizations ([link removed]) involved in adolescent vaccination, personal stories ([link removed]) about the importance of vaccination, and otherresources ([link removed]) of interest
The site also categorizes materials ([link removed]) according to whether they are primarily of interest to providers, to adolescents, or to parents.
Visit Give2MenACWY.org ([link removed]) and enjoy browsing (and deploying) its bountiful resources.
Related Links
* Give2MenACWY.org ([link removed]) website
* Algorithm for MenACWY Immunization in Adolescents 11–18 Years of Age ([link removed])
* MenACWY: You're Not Done If You Give Just One: Give 2 Doses to Strengthen Protection ([link removed])
* Recommending MenACWY: What to Say and How to Say It ([link removed])
* Top 10 Ways to Improve Adolescent Immunization Rates ([link removed])
* Developing an Immunization Culture in Your Office ([link removed])
* Know Your Rates: Measuring Immunization Success in Your Practice ([link removed])
* You're 16: We Recommend These Vaccines for You ([link removed])
* Dear Colleague Letter: 16-Year-Old Patients: Make Sure They Receive Their Annual Well Visit and Vaccinations ([link removed]) , signed by six medical societies
* Ask the Experts: Meningococcal ACWY ([link removed])
* CDC: ACIP Meningococcal Vaccine Recommendations ([link removed])
* CDC: Vaccination Coverage Among Adolescents Aged 13–17 Years—National Immunization Survey–Teen, United States, 2023 ([link removed])
Back to top (#Top)
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Register for Immunize.org Website Office Hours. Join a 30-minute discussion about the VIS web section on September 10 at 4:00 p.m. (ET) or September 11 at 12:00 p.m. (ET). Recorded sessions archived.
To learn simple tips and tricks for using our website efficiently, please register for our next set of Website Office Hours on Wednesday, September 10, at 4:00 p.m. (ET) ([link removed]) or Thursday, September 11, at 12:00 p.m. (ET) ([link removed]) . The same content will be covered in both sessions.
We will open each 30-minute session with a short, live demonstration on navigating the popular VIS website section on Immunize.org. You can submit questions when you register or live on Zoom during the session.
[link removed]
Register today for Immunize.org Website Office Hours (content is the same for both):
* Wednesday, September 10, at 4:00 p.m. (ET) ([link removed])
* Thursday, September 11, at 12:00 p.m. (ET) ([link removed])
The archive of previous Website Office Hours content ([link removed]) is posted at Immunize.org’s "Webinars & Videos" page.
Mark your calendar ([link removed]) for future Immunize.org Website Office Hours.
Back to top (#Top)
------------------------------------------------------------
Virtual: Public Health Communications Collaborative offers webinar titled “Communicating with Heart in Public Health” on September 10 at 4:30 p.m. (ET)
The Public Health Communications Collaborative (PHCC) ([link removed]) will host a webinar titled Communicating with Heart in Public Health ([link removed]) at 4:30 p.m. (ET) on September 10. The webinar will explore how active, intentional listening can deepen our understanding of our communities’ needs, beliefs, and lived experiences for more effective communication. Building on PHCC’s H.E.A.R.T. framework ([link removed]) , attendees will gain tips, tools, and real examples on communicating public health guidance and data with care and clarity.
PHCC was formed in August 2020 by the CDC Foundation, the de Beaumont Foundation, and Trust for America’s Health to provide unbiased communication about the COVID-19 pandemic. Since then, PHCC has added new partners and broadened its mission beyond the COVID-19 pandemic.
[link removed]
Register for the webinar ([link removed]) and submit your questions online.
Back to top (#Top)
------------------------------------------------------------
Virtual: Maternal Immunization Task Force offers webinar titled “Preparing for Respiratory Virus Season: A Review of Maternal Immunization Guidance and Communication Strategies to Increase Vaccine Uptake and Confidence” on September 17 at 5:00 p.m. (ET)
The Maternal Immunization Task Force ([link removed]) led by the American College of Obstetricians and Gynecologists, will host a webinar titled Preparing for Respiratory Virus Season: A Review of Maternal Immunization Guidance and Communication Strategies to Increase Vaccine Uptake and Confidence ([link removed]) at 5:00 p.m. (ET) on September 17. The webinar is designed to support healthcare professionals seeking to protect pregnant patients and their families against COVID-19, influenza, and RSV. Experts will discuss ways to address common patient concerns and provide strategies to best communicate with and educate the public about respiratory viruses and vaccines.
[link removed]
Register for the webinar ([link removed]) and submit your questions for the experts.
Back to top (#Top)
------------------------------------------------------------
Virtual: September 18–19 ACIP meeting announced; discussion and possible votes on COVID-19, hepatitis B, MMRV, and RSV vaccines planned
CDC is scheduled to convene the ACIP on September 18–19 ([link removed]) . Based on ahttps://public-inspection.federalregister.gov/2025-16706.pdfnotice in the Federal Register ([link removed]) , the meeting will discuss and potentially vote on COVID-19, hepatitis B, MMRV, and RSV vaccines. An agenda has not yet been posted.
Written public comments ([link removed]) and registration for oral public comments must be received between September 2–13.
[link removed]
No registration is required to watch webcasts of live ACIP meetings or listen via telephone.
Related Links
* CDC: ACIP main page ([link removed]) for access to webcast, agendas
* CDC: ACIP: Meeting Information ([link removed]) for presentation slides, content from previous meetings, and information about future meetings
Back to top (#Top)
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]) .
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Gr
äbenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]) .
IZ Express is supported in part by Grant No. NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer (http:// [link removed])
ISSN: 2771-8085
This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
Immunize.org . 2136 Ford Parkway . Suite 5011 . Saint Paul, MN 55116 . USA
Email not displaying correctly? View it in your browser. ([link removed])
[link removed]
Issue 1,830: September 3, 2025
Top Stories
* Immunize.org’s commitment to sharing clinical vaccination guidance based on the best available scientific evidence (#IZ1)
* “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025–26 Influenza Season” published in MMWR (#IZ2)
* Immunize.org’s standing order templates for the 2025–26 influenza season are now available (#IZ3)
* “Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025” published in MMWR (#IZ4)
* American College of Cardiology publishes clinical guidance for adults with cardiovascular disease, encouraging influenza, pneumococcal, COVID-19, RSV, zoster, and other vaccinations (#IZ5)
* FDA licenses updated COVID-19 vaccines for 2025–26 season with limited indications for people younger than age 65 (#IZ6)
* Immunize.org updates “Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy” to reference both preventive antibody options for infant RSV prevention (#IZ7)
* FDA suspends license for chikungunya vaccine live (Ixchiq, Valneva) based on safety concerns involving chikungunya-like illness (#IZ8)
* Immunize.org updates “Meningococcal B Vaccine Recommendations by Age and Risk Factor” to include both pentavalent MenABCWY vaccine options (#IZ9)
* Immunize.org updates resource “Before You Vaccinate Adults, Consider Their ‘H-A-L-O’!” (#IZ10)
* Confirmed measles cases in 2025 increase to 1,408 across 42 states; Alabama reports first case for 2025 (#IZ11)
* “Do Parents Have a Choice of How to Prevent RSV in Their Newborn?” Watch the 2-minute answer, part of the Ask the Experts Video Series on YouTube. (#IZ12)
* Journalists interview Immunize.org experts (#IZ13)
* Vaccines in the news (#IZ14)
Immunize.org Website and Clinical Resources
* Spotlight on the LetsGetRealAboutVaccines.org website: Help Patients (#IZ15)
* Recap: Immunize.org posts RSV preventive antibody standing order templates for clesrovimab (new) and nirsevimab (updated) (#IZ16)
* Summary: Updated Immunize.org clinical resources released in July and August (#IZ17)
Featured Resources
* Explore the www.Give2MenACWY.org website to increase coverage for the MenACWY booster and other adolescent vaccinations (#IZ18)
Upcoming Events
* Virtual: Register for Immunize.org Website Office Hours. Join a 30-minute discussion about the VIS web section on September 10 at 4:00 p.m. (ET) or September 11 at 12:00 p.m. (ET). Recorded sessions archived. (#IZ19)
* Virtual: Public Health Communications Collaborative offers webinar titled “Communicating with Heart in Public Health” on September 10 at 4:30 p.m. (ET) (#IZ20)
* Virtual: Maternal Immunization Task Force offers webinar titled “Preparing for Respiratory Virus Season: A Review of Maternal Immunization Guidance and Communication Strategies to Increase Vaccine Uptake and Confidence” on September 17 at 5:00 p.m. (ET) (#IZ21)
* Virtual: September 18–19 ACIP meeting announced; discussion and possible votes on COVID-19, hepatitis B, MMRV, and RSV vaccines planned (#IZ22)
Editorial Information (#Editorial)
------------------------------------------------------------
Top Stories
------------------------------------------------------------
Immunize.org’s commitment to sharing clinical vaccination guidance based on the best available scientific evidence
The recent changes to the membership of ACIP and resignation of respected scientific leaders at CDC have raised serious concerns across public health and healthcare communities. Information shared by the departing CDC leaders have raised doubts about the scientific validity of vaccine policies contemplated by the current administration. In addition, we observed the June ACIP vote against the use of thimerosal-containing influenza vaccines, a decision made without following the standard rigorous review of available data or the structured evidence-to-recommendations framework. In response, professional medical societies (e.g., American Academy of Pediatrics, American College of Obstetricians and Gynecologists) have begun to issue vaccination guidance that differs from new CDC guidance. Vaccination providers and educators who depend on Immunize.org resources should understand how we are approaching this unprecedented situation.
First, Immunize.org will continue to ensure vaccination providers know what CDC and ACIP recommend. Their recommendations directly affect VFC, Medicaid, and Medicare vaccine coverage, and could impact other insurance plan coverage. Federal recommendations may also define the permitted scope of practice for some vaccinators, including pharmacists, depending upon state regulations. We will provide context to help our readers understand when available scientific evidence does not support federal guidance.
Second, we will continue to educate vaccinators and share the best available evidence-based clinical information and guidance for vaccination. This may include adding links to the recommendations and published schedules of professional societies or other broadly accepted clinical guidance organizations. When we update resources with guidance from other credible scientific sources, we will be explicit about where that guidance came from and connect you to those sources.
Our goal is to support you to be able to make the best possible clinical practice decisions and provide the best available vaccination advice to your patients and families. To this end, our popular standing orders templates will include CDC recommendations and, when needed, refer to major professional society recommendations where there are important differences. As always, our standing orders templates should be adapted as needed to develop the standing orders you use in specific settings.
Immunize.org is in the process of determining the best ways to reflect these differences on our website clearly and concisely. We commit to keeping you, our readers and partners, informed as we proceed. We remain committed to supporting you and members of the public with trustworthy vaccination information and resources.
Back to top (#Top)
------------------------------------------------------------
“Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025–26 Influenza Season” published in MMWR
CDC published Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025–26 Influenza Season ([link removed]) on August 28 in MMWR. A portion of the summary appears below.
Information for the 2025–26 influenza season includes the updated vaccine composition, approval of FluMist (nasal spray live attenuated influenza vaccine) for self-administration or caregiver administration, expansion of the approved age threshold for Flublok (recombinant influenza vaccine) from ≥18 years to ≥9 years, and a recommendation that only single-dose seasonal influenza vaccines not containing thimerosal as a preservative be used. . . .
Routine annual influenza vaccination is recommended for all persons aged ≥6 months without a contraindication to vaccination to protect against influenza and its complications.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Links
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
* CDC: ACIP Recommendations: Influenza (Flu) Vaccine ([link removed]'s%20no%20need%20to%20wait,dose%201%20and%20dose%202) main page
* AAP:[link removed]'s%20no%20need%20to%20wait,dose%201%20and%20dose%202Which Flu Vaccine Should Children Get? ([link removed]) web page
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) main page
Back to top (#Top)
------------------------------------------------------------
Immunize.org’s standing order templates for the 2025–26 influenza season are now available
Immunize.org’s popular standing orders templates for the 2025–26 influenza season are now available. These templates help you simplify providing influenza vaccine to people in your practice age 6 months and older, whether you are using an injectable influenza vaccine or a live attenuated influenza vaccine.
* Standing Orders for Administering Influenza Vaccine to Adults ([link removed])
* Standing Orders for Administering Influenza Vaccine to Children and Teens ([link removed])
These templates are designed to be used with any formulation of influenza vaccine. They acknowledge the June 2025 ACIP vote to no longer recommend use of multi-dose vial formulations containing thimerosal as a preservative and note that CDC’s website ([link removed]) states (as of 8/30/2025) that there is no evidence of harm caused by the low doses of thimerosal in vaccines, other than minor reactions like redness and swelling at the injection site.
[link removed] [link removed]
Influenza Vaccine Products for the 2025–2026 Influenza Season ([link removed]) , Immunize.org’s one-page reference document, is also available. For each vaccine, the manufacturer, trade name, common abbreviation, dosage form, mercury content, age range, vaccine product (CVX) code, and product billing (CPT) code are listed.
[link removed]
Related Links
* Immunize.org: Vaccines A–Z: Influenza ([link removed]) web page
* Immunize.org: Clinical Resources: Standing Orders Templates ([link removed]) main page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
“Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025” published in MMWR
CDC published Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025 ([link removed]) on August 28 in MMWR. A portion of the summary appears below.
To prevent respiratory syncytial virus (RSV)–associated lower respiratory tract infection (LRTI) in infants, since 2023, the Advisory Committee on Immunization Practices (ACIP) has recommended either 1) maternal RSV vaccination during pregnancy or 2) administration of nirsevimab, a long-acting RSV monoclonal antibody, to the infant. . . .
On June 26, 2025, ACIP recommended clesrovimab, a newly licensed long-acting RSV monoclonal antibody, as an alternative to nirsevimab for infants aged <8 months born during or entering their first RSV season who did not receive protection through maternal RSV vaccination. . . .
All infants should be protected against RSV LRTI through either maternal RSV vaccination or receipt of a long-acting RSV monoclonal antibody (clesrovimab or nirsevimab).
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]) .
Related Links
* CDC: MMWR main page ([link removed]) providing access to the MMWR family of publications
* Immunize.org: Standing Orders for Administering Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants ([link removed])
Back to top (#Top)
------------------------------------------------------------
American College of Cardiology publishes clinical guidance for adults with cardiovascular disease, encouraging influenza, pneumococcal, COVID-19, RSV, zoster, and other vaccinations
On August 26, the American College of Cardiology (ACC) published 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Adult Immunizations as Part of Cardiovascular Care: A Report of the American College of Cardiology Solution Set Oversight Committee ([link removed]) . A portion of the introduction appears below.
This CCG [Concise Clinical Guidance] provides current recommendations for vaccination in patients with cardiovascular disease along with more detailed justifications for those interested in the evidence influencing these recommendations. The intended audience is clinicians managing patients with cardiovascular disease (CVD). We include recommendations from existing ACC/American Heart Association (AHA) Guidelines and the Centers for Disease Control and Prevention (CDC) that are relevant, and evidence based. A Frequently Asked Questions section also provides information that can be used for patient discussions. The topic was selected by the ACC Science and Quality Committee. A summary of the recommendations is shown in Table 1.
[link removed]
The guidelines highlight helpful supplementary material, including patient handouts and communication approaches for cardiologists.
* Protect Your Heart with the Vaccines You Need ([link removed]) : an infographic to display in clinical settings, such as exam rooms or waiting rooms, to inform patients with heart disease about the vaccines they need to stay healthy
* Communication Approaches to Help Make a Strong Vaccine Recommendation ([link removed]) : a 17-page guide with practical tips to enhance conversations with patients about the importance of adult vaccines
[link removed] [link removed]
Related Links
* Immunize.org: Vaccinations for Adults with Heart Disease ([link removed])
* Immunize.org: Vaccinations for Adults with Heart Disease (Spanish) ([link removed])
Back to top (#Top)
------------------------------------------------------------
FDA licenses updated COVID-19 vaccines for 2025–26 season with limited indications for people younger than age 65
On August 27, FDA licensed updated COVID-19 vaccines for the 2025–26 season. The package insert indications were narrowed to include use in all people who are age 65 years and older and certain people younger than age 65 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. The indicated age ranges vary by vaccine, as described below.
Package inserts and approval letters appear at the links below.
* Spikevax (COVID-19 Vaccine, mRNA; Moderna) ([link removed]) : age 6 months through 64 years with an underlying condition and all adults age 65 years and older
* Comirnaty (COVID-19 Vaccine, mRNA; Pfizer/BioNTech) ([link removed]) : age 5 through 64 years with an underlying condition and all adults age 65 years and older
* Mnexspike (COVID-19 Vaccine, mRNA; Moderna) ([link removed]) : age 12 through 64 years with an underlying condition and all adults age 65 years and older
* Nuvaxovid (COVID-19 Vaccine, Adjuvanted; Novavax) ([link removed]) : age 12 through 64 years with an underlying condition and all adults age 65 years and older
At its September 18–19 meeting ([link removed]) , ACIP is scheduled to consider its recommendations for use of available COVID-19 vaccines.
In response to these limited indications, the Infectious Diseases Society of America (IDSA) ([link removed]) and the American Academy of Pediatrics (AAP) ([link removed]) each expressed serious concerns. Portions of their press releases appear below.
IDSA Statement (8/27/25): ([link removed])
COVID-19 vaccines remain our best tool to prevent severe disease, hospitalization and death due to COVID-19 — for healthy adults, children, pregnant patients and others at higher risk. The scientific evidence continues to strongly support broad vaccination far beyond the limited populations outlined in the Food and Drug Administration’s new label.
AAP Statement (8/27/25): ([link removed])
As we enter respiratory virus season, any barrier to COVID-19 vaccination creates a dangerous vulnerability for children and their families. Respiratory illnesses can be especially risky for infants and toddlers, whose airways and lungs are small and still developing.
Related Links
* Immunize.org: Vaccines A–Z: COVID-19 ([link removed]) main page
* FDA: Vaccines Licensed for Use in the United States ([link removed]) web page
* AAP: Recommended Child and Adolescent Immunization Schedules for Ages 18 Years or Younger, United States, 2025 ([link removed])
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates “Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy” to reference both preventative antibody options for infant RSV prevention
Immunize.org updated its Standing Orders for Administering Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy ([link removed]) , to note the options to use nirsevimab (Beyfortus ([link removed]) , Sanofi) or clesrovimab (Enflonsia, Merck) ([link removed]) for infant RSV protection if the mother was not effectively vaccinated during her pregnancy.
[link removed]
Related Links
* Immunize.org: Clinical Resources: Standing Orders Templates ([link removed]) main page
* Immunize.org: Vaccines A–Z: RSV (Respiratory Syncytial Virus) ([link removed]) main page
* Immunize.org: Standing Orders for Administering Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants ([link removed])
* Immunize.org: Standing Orders for Administering Nirsevimab RSV Preventive Antibody (Beyfortus, by Sanofi) to Infants and High-Risk Young Children ([link removed])
Back to top (#Top)
------------------------------------------------------------
FDA suspends license for chikungunya vaccine live (Ixchiq, Valneva) based on safety concerns involving chikungunya-like illness
On August 22, FDA suspended the license ([link removed]) for the live chikungunya vaccine Ixchiq (Valneva) ([link removed]) . This vaccine was initially approved by FDA in November 2023 ([link removed]) for the prevention of disease caused by chikungunya virus (CHIKV) in adults at increased risk of exposure to CHIKV. Concerns about side effects of this vaccine were first raised at the ACIP meeting in April 2025, when CDC presented details of six U.S. vaccine recipients age 65 years or older ([link removed]) , each with other health conditions, who developed cardiac or neurologic symptoms requiring hospitalization within days of vaccination. After additional monitoring and
reports of 20 similar serious illnesses in the United States and other countries, FDA suspended the license. One death from encephalitis attributed to the vaccine was reported from another country.
The viral-like particle chikungunya vaccine (Vimkunya, Bavarian Nordic), licensed in the United States in February 2025 for people age 12 years and older, continues to be recommended for use. It is not a live vaccine and is not associated with the safety concerns identified with the live-attenuated vaccine.
According to the European Centre for Disease Prevention and Control ([link removed]) , from January to July 2025 around 240,000 chikungunya cases and 90 related deaths have been reported in 16 countries or territories in the Americas, Africa, Asia, and Europe.
Related Links
* Valneva: Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. ([link removed]) (8/25/25)
* FDA: FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live) ([link removed]) web page
* CDC: Chikungunya Vaccine Information for Healthcare Providers ([link removed]) web page
* Immunize.org: Vaccines A–Z: Chikungunya ([link removed]) main page
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates “Meningococcal B Vaccine Recommendations by Age and Risk Factor” to include both pentavalent MenABCWY vaccine options
Immunize.org updated Meningococcal B Vaccine Recommendations by Age and Risk Factor ([link removed] ) to add the second pentavalent MenABCWY vaccine (Penmenvy, GSK ([link removed]) ([link removed]) ) in addition to Penbraya (Pfizer).
[link removed]
Related Link
* Immunize.org: Vaccines A–Z: Meningococcal B ([link removed]) web page
Back to top (#Top)
------------------------------------------------------------
Immunize.org updates resource “Before You Vaccinate Adults, Consider Their ‘H-A-L-O’!”
Immunize.org recently updated its popular resource for healthcare professionals titled Before You Vaccinate Adults, Consider Their “H-A-L-O” ([link removed]) !
H-A-L-O refers to four factors:
* Health condition
* Age
* Lifestyle
* Occupation
Edits incorporate the age 50 threshold for adults with risk factors to receive RSV vaccine and referral to current recommendations for COVID-19 vaccine.
[link removed]
Related Links
* Immunize.org: Clinic Tools: Vaccine Recommendations ([link removed]) web page
* Immunize.org: Clinical Resources A–Z ([link removed]) main page, where you can filter by topic, vaccine, language, or other criteria
Back to top (#Top)
------------------------------------------------------------
Confirmed measles cases in 2025 increase to 1,408 across 42 states; Alabama reports first case for 2025
As of August 27, CDC reported 1,408 confirmed measles cases ([link removed]) in 2025 in 42 states. Of reported confirmed cases, 28% were younger than age 5 years and 21% were hospitalized. Canada reports 4,718 confirmed and probable cases for 2025 through August 16.
CDC only requires reporting of laboratory-confirmed measles cases. Cases without laboratory testing for confirmation are not included in these numbers. Actual numbers of cases are, therefore, higher than confirmed case counts.
A map of 2025 measles cases ([link removed]) in the contiguous United States, as of August 25, from the Johns Hopkins International Vaccine Access Center ([link removed]) , appears below. The U.S. Measles Tracker ([link removed]) website includes state and county-level data.
[link removed]
Immunize.org offers measles-related resources for the public on several of our affiliated websites:
* VaccineInformation.org: Measles ([link removed]) web page
* LetsGetRealAboutVaccines.org: Measles ([link removed]) web page
* Immunize.org: Vaccines A–Z: Measles ([link removed]) main page
Another credible source is the American Academy of Pediatrics’ Fact Checked: The Measles Vaccine is Safe and Effective ([link removed]) web page.
Related Links
* CDC: Measles Cases and Outbreaks ([link removed]) main page
* CDC: Be Ready for Measles Toolkit ([link removed])
* Health Canada: Measles and Rubella Weekly Monitoring Report ([link removed])
* Johns Hopkins Bloomberg School of Public Health Center for Outbreak Response Innovation: Measles Outbreak Response ([link removed]) main page
* Immunize.org: Vaccines A–Z: Measles ([link removed]) main page
Back to top (#Top)
------------------------------------------------------------
“Do Parents Have a Choice of How to Prevent RSV in Their Newborn?” Watch the 2-minute answer, part of the Ask the Experts Video Series on YouTube.
This week, our featured episode from the Ask the Experts Video Series is titled Do Parents Have a Choice of How to Prevent RSV in Their Newborn? ([link removed] ) The video describes that mothers have options to choose Abrysvo, Pfizer’s brand of RSV vaccine during pregnancy or an RSV preventive antibody product for the infant after birth.
The 2-minute video is available on our YouTube channel ([link removed]) , along with our full collection of quick video answers to popular Ask the Experts ([link removed]) questions.
[link removed]
Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
* Facebook at ImmunizeOrg ([link removed])
* Instagram at ImmunizeOrg ([link removed])
* LinkedIn at ImmunizeOrg ([link removed])
* YouTube at ImmunizeOrg ([link removed])
Back to top (#Top)
------------------------------------------------------------
Journalists interview Immunize.org experts
Journalists seek out Immunize.org experts to help explain vaccines to the public and policy makers. We help the media understand and communicate the complex work vaccinators do. Here is a recent citation.
* CNN: After Narrowing COVID-19 Vaccine Approval, the FDA Says Healthy People Can Still Get It. But Access Might Be Complicated ([link removed]) (8/29/25)
* NPR: The Latest COVID Vaccines Come with New FDA Limits ([link removed]) (8/27/25)
Back to top (#Top)
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* New York Times: We Ran the C.D.C.: Kennedy Is Endangering Every American’s Health ([link removed]) (commentary, 9/01/25)
* CBS: CVS and Walgreens Limit Access to COVID Vaccines as Required by Some State Guidelines ([link removed]) (8/29/25)
* Medpage Today: I Was Inside CDC During the Shooting. I Can Still Hear the Bullets. ([link removed]) (8/26/25)
* USA Today: Vaccine Skepticism Crisis Spills Over as Students Return to School ([link removed]) (8/25/25)
* PBS: Fact-Checking RFK Jr.’s Claim That Pediatricians Recommend Vaccines for Money ([link removed]) (8/24/25)
Back to top (#Top)
------------------------------------------------------------
Immunize.org Website and Clinical Resources
------------------------------------------------------------
Spotlight on the LetsGetRealAboutVaccines.org website: Help Patients
This week’s spotlight completes the review of our newest website, LetsGetRealAboutVaccines.org ([link removed]) , a trustworthy, parent-friendly platform that delivers factual vaccine guidance. It equips families and providers with tools to advocate for childhood immunization confidently.
This week’s focus is on the Help Patients ([link removed]) section. Found at the fourth menu tab, these pages share strategies for healthcare providers to communicate effectively with parents about vaccination.
[link removed]
The ARM Approach ([link removed]) for healthcare providers is an evidence-based, provider-reviewed, three-step approach (Act, Recommend, Motivate) to fruitful vaccine conversations with parents and patients. Content includes what, why, and how of making strong recommendations, and best practices to help patients make informed decisions.
Resources to use and share:
* Making effective recommendations [PDF ([link removed]) ]
* Sample outreach scripts and best practices [PDF] ([link removed])
* Videos
+ Dr. Marcy Solomon Baker ([link removed]) confirms most parents get their kids vaccinated
+ Dr. Todd Wolynn ([link removed]) explains that misinformation does not change the facts: vaccines are safe and effective
* Tips and timesavers [PDF ([link removed]) ]
Share these links with anyone seeking credible, unbiased information about childhood vaccines.
View the archived Website Office Hours: Let's Get Real About Vaccines ([link removed]) website webinar to learn simple tips and tricks for using the website efficiently.
Back to top (#Top)
------------------------------------------------------------
Recap: Immunize.org posts RSV preventive antibody standing order templates for clesrovimab (new) and nirsevimab (updated)
In response to new CDC recommendations for routine use of an additional RSV preventive antibody product in infants, Immunize.org published the clinical resource: Standing Order for Administering Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants ([link removed]) . Immunize.org also updated its existing Standing Order for Administering Nirsevimab RSV Preventive Antibody (Beyfortus, by Sanofi) to Infants and High-Risk Young Children ([link removed]) .
The new preventive antibody product, Enflonsia, is an option for protection of infants younger than age 8 months before or during their first RSV season. There is no preference between Beyfortus and Enflonsia for eligible infants. The Beyfortus standing orders template was updated to note that the other two options for protection of infants during their first RSV season are to administer Enflonsia to the infant or to administer the Abrysvo RSV vaccine (Pfizer) during pregnancy. Only Beyfortus is licensed and recommended for older children, age 8 through 19 months, who are at high risk for severe RSV disease and are entering their second RSV season.
Back to top (#Top)
------------------------------------------------------------
Summary: Updated Immunize.org clinical resources released in July and August
IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials for healthcare professionals and handouts for patients. All Immunize.org materials are free to distribute.
In case you missed them during recent weeks, the following new and updated materials were posted:
Immunize.org Materials for Clinicians
Standing Orders Templates for Administering:
* Respiratory Syncytial Virus Vaccine (RSV) to Adults Age 50 Years and Older ([link removed])
* Pfizer Respiratory Syncytial Virus (RSV) Vaccine (Abrysvo) During Pregnancy ([link removed])
* Nirsevimab RSV Preventive Antibody (Beyfortus, by Sanofi) to Infants and High-Risk Young Children ([link removed])
* Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants ([link removed])
* Zoster Vaccine (Shingrix) ([link removed])
Materials Supporting Immunization Services:
* Influenza Vaccine Products for the 2025–2026 Influenza Season ([link removed])
* Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed])
Immunize.org Webinars:
* Website Office Hours: Let's Get Real About Vaccines Website ([link removed])
* Website Office Hours: Official Guidance – State Resources ([link removed])
State Immunization Requirements, Exemptions, and Related Websites:
* COVID-19 Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* DTaP (Diphtheria-Tetanus-Pertussis) Vaccine Requirements for Childcare and Elementary School ([link removed]) as of May 2025
* Hepatitis A Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* Hepatitis B Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* Hepatitis B Vaccine Requirements for Colleges and Universities ([link removed]) as of May 2025
* Hib Vaccine Requirements for Childcare ([link removed]) as of May 2025
* HPV (Human Papillomavirus) Vaccine Requirements for Secondary School ([link removed]) as of May 2025
* Influenza Vaccine Requirements for Childcare and Pre-K ([link removed]) as of May 2025
* Meningococcal ACWY (MenACWY) Vaccine Requirements for Secondary School ([link removed]) as of May 2025
* Meningococcal ACWY (MenACWY) Vaccine Requirements for Colleges and Universities ([link removed]) as of May 2025
* MMR (Measles-Mumps-Rubella) Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* Pneumococcal Conjugate Vaccine (PCV) Requirements for Childcare ([link removed]) as of May 2025
* Polio Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* Rotavirus Vaccine Requirements for Childcare ([link removed]) as of May 2025
* Tdap (Tetanus-Diphtheria-Pertussis) Vaccine Requirements for Secondary School ([link removed]) as of May 2025
* Varicella Vaccine Requirements for Childcare and School (K–12) ([link removed]) as of May 2025
* Exemptions Permitted for State Childcare and School (K–12) Immunization Requirements ([link removed]) as of May 2025
* State Immunization Websites ([link removed])
Back to top (#Top)
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Explore the www.Give2MenACWY.org website to increase coverage for the MenACWY booster and other adolescent vaccinations
Immunize.org's www.Give2MenACWY.org ([link removed]) website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines, so vaccine outreach is more important than ever.
Materials on this colorful website for healthcare professionals incorporate the 2020 ACIP meningococcal vaccine recommendations ([link removed]) and coverage statistics from CDC’s National Immunization Survey–Teen (NIS–Teen). One particularly popular resource on the site is the Algorithm for MenACWY Immunization in Adolescents 11 Through 18 Years of Age ([link removed]) .
[link removed]
The website is divided into five easy-to-access sections:
* Vaccinate Teens ([link removed]) : teen vaccination schedules and tips for improving vaccination rates
* Give 2 Doses ([link removed]) : tools to help improve second dose coverage of MenACWY vaccine
* 16-Year-Old Visit ([link removed]) : resources to help providers and patients remember the important vaccines recommended for 16-year-olds
* Tools for Providers ([link removed]) : tools to explain meningococcal ACWY vaccine recommendations and improve coverage for all adolescent vaccines
* Resources ([link removed]) : links to print materials ([link removed]) , organizations ([link removed]) involved in adolescent vaccination, personal stories ([link removed]) about the importance of vaccination, and otherresources ([link removed]) of interest
The site also categorizes materials ([link removed]) according to whether they are primarily of interest to providers, to adolescents, or to parents.
Visit Give2MenACWY.org ([link removed]) and enjoy browsing (and deploying) its bountiful resources.
Related Links
* Give2MenACWY.org ([link removed]) website
* Algorithm for MenACWY Immunization in Adolescents 11–18 Years of Age ([link removed])
* MenACWY: You're Not Done If You Give Just One: Give 2 Doses to Strengthen Protection ([link removed])
* Recommending MenACWY: What to Say and How to Say It ([link removed])
* Top 10 Ways to Improve Adolescent Immunization Rates ([link removed])
* Developing an Immunization Culture in Your Office ([link removed])
* Know Your Rates: Measuring Immunization Success in Your Practice ([link removed])
* You're 16: We Recommend These Vaccines for You ([link removed])
* Dear Colleague Letter: 16-Year-Old Patients: Make Sure They Receive Their Annual Well Visit and Vaccinations ([link removed]) , signed by six medical societies
* Ask the Experts: Meningococcal ACWY ([link removed])
* CDC: ACIP Meningococcal Vaccine Recommendations ([link removed])
* CDC: Vaccination Coverage Among Adolescents Aged 13–17 Years—National Immunization Survey–Teen, United States, 2023 ([link removed])
Back to top (#Top)
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Register for Immunize.org Website Office Hours. Join a 30-minute discussion about the VIS web section on September 10 at 4:00 p.m. (ET) or September 11 at 12:00 p.m. (ET). Recorded sessions archived.
To learn simple tips and tricks for using our website efficiently, please register for our next set of Website Office Hours on Wednesday, September 10, at 4:00 p.m. (ET) ([link removed]) or Thursday, September 11, at 12:00 p.m. (ET) ([link removed]) . The same content will be covered in both sessions.
We will open each 30-minute session with a short, live demonstration on navigating the popular VIS website section on Immunize.org. You can submit questions when you register or live on Zoom during the session.
[link removed]
Register today for Immunize.org Website Office Hours (content is the same for both):
* Wednesday, September 10, at 4:00 p.m. (ET) ([link removed])
* Thursday, September 11, at 12:00 p.m. (ET) ([link removed])
The archive of previous Website Office Hours content ([link removed]) is posted at Immunize.org’s "Webinars & Videos" page.
Mark your calendar ([link removed]) for future Immunize.org Website Office Hours.
Back to top (#Top)
------------------------------------------------------------
Virtual: Public Health Communications Collaborative offers webinar titled “Communicating with Heart in Public Health” on September 10 at 4:30 p.m. (ET)
The Public Health Communications Collaborative (PHCC) ([link removed]) will host a webinar titled Communicating with Heart in Public Health ([link removed]) at 4:30 p.m. (ET) on September 10. The webinar will explore how active, intentional listening can deepen our understanding of our communities’ needs, beliefs, and lived experiences for more effective communication. Building on PHCC’s H.E.A.R.T. framework ([link removed]) , attendees will gain tips, tools, and real examples on communicating public health guidance and data with care and clarity.
PHCC was formed in August 2020 by the CDC Foundation, the de Beaumont Foundation, and Trust for America’s Health to provide unbiased communication about the COVID-19 pandemic. Since then, PHCC has added new partners and broadened its mission beyond the COVID-19 pandemic.
[link removed]
Register for the webinar ([link removed]) and submit your questions online.
Back to top (#Top)
------------------------------------------------------------
Virtual: Maternal Immunization Task Force offers webinar titled “Preparing for Respiratory Virus Season: A Review of Maternal Immunization Guidance and Communication Strategies to Increase Vaccine Uptake and Confidence” on September 17 at 5:00 p.m. (ET)
The Maternal Immunization Task Force ([link removed]) led by the American College of Obstetricians and Gynecologists, will host a webinar titled Preparing for Respiratory Virus Season: A Review of Maternal Immunization Guidance and Communication Strategies to Increase Vaccine Uptake and Confidence ([link removed]) at 5:00 p.m. (ET) on September 17. The webinar is designed to support healthcare professionals seeking to protect pregnant patients and their families against COVID-19, influenza, and RSV. Experts will discuss ways to address common patient concerns and provide strategies to best communicate with and educate the public about respiratory viruses and vaccines.
[link removed]
Register for the webinar ([link removed]) and submit your questions for the experts.
Back to top (#Top)
------------------------------------------------------------
Virtual: September 18–19 ACIP meeting announced; discussion and possible votes on COVID-19, hepatitis B, MMRV, and RSV vaccines planned
CDC is scheduled to convene the ACIP on September 18–19 ([link removed]) . Based on ahttps://public-inspection.federalregister.gov/2025-16706.pdfnotice in the Federal Register ([link removed]) , the meeting will discuss and potentially vote on COVID-19, hepatitis B, MMRV, and RSV vaccines. An agenda has not yet been posted.
Written public comments ([link removed]) and registration for oral public comments must be received between September 2–13.
[link removed]
No registration is required to watch webcasts of live ACIP meetings or listen via telephone.
Related Links
* CDC: ACIP main page ([link removed]) for access to webcast, agendas
* CDC: ACIP: Meeting Information ([link removed]) for presentation slides, content from previous meetings, and information about future meetings
Back to top (#Top)
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]) .
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Gr
äbenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles.
When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]) .
IZ Express is supported in part by Grant No. NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer (http:// [link removed])
ISSN: 2771-8085
This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
Immunize.org . 2136 Ford Parkway . Suite 5011 . Saint Paul, MN 55116 . USA
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp